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Abstract
The influence of endotoxin-induced elevated plasma levels of the
fast-acting inhibitor of plasminogen activator (PA-inhibitor) on
thrombolysis was investigated in rabbits with a jugular vein
thrombus. Infusion of human tissue-type plasminogen activator
(t-PA) produced similar degrees of thrombolysis in control and
endotoxin-treated rabbits, although no free t-PA could be dem-
onstrated in plasma of endotoxin-treated animals. Infusion of
t-PA in an extracorporeal arteriovenous shunt resulted in loss
of thrombolytic activity in endotoxin-treated animals but not in
control animals.
Blood clots superfused in vitro with mixtures of t-PA and
normal plasma lysed in contrast to clots superfused with t-PA
and PA-inhibitor-rich plasma. However, addition of rabbit lung
slices to the plasma surrounding the blood clot, reversed the
inhibition of thrombolysis by PA-inhibitor-rich plasma. This in-
dicates that tissue-derived factor(s) are involved in the regulation
of in vivo thrombolysis. These hypothetical factor(s) are, how-
ever, very unstable in plasma, which has thus far precluded their
further characterization.
Introduction
Fibrin plays an important role in the regulation of fibrinolysis
(1). It markedly stimulates the activation of plasminogen by
tissue-type plasminogen activator (t-PA)' and protects plasmin
molecules, generated at the clot surface, from rapid inhibition
by a2-antiplasmin. It thereby mediates effective and clot-specific
activation of the fibrinolytic system.
Human plasma and conditioned medium from endothelial
cell cultures contain a fast-acting inhibitor of plasminogen ac-
tivator (PA-inhibitor) that neutralizes both t-PA and urokinase
(UK) (2-9). PA-inhibitor has an apparent molecular mass of
40-50 kD and forms an inactive 1:1 molar complex with t-PA
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(and UK) (8, 9). The reaction between t-PA and PA-inhibitor
is very rapid, with a rate constant of 107 M-1 s-' (2, 3). Rapid
inhibition of t-PA by PA-inhibitor has also been demonstrated
in vivo (10). The plasma concentration ofPA-inhibitor in healthy
subjects is in the nanograms per milliliter range (2-6) but is
markedly increased in some pathological conditions (3, 4), and
in conditions associated with low fibrinolytic activity and a
thrombotic tendency (1 1-13).
Little is known about the effect of fibrin on the interaction
between t-PA and PA-inhibitor. Kruithof et al. (2) observed that
coagulation of PA-inhibitor-rich plasma prevented the inhibition
of t-PA. Zamarron et al. (14), however, concluded that PA-in-
hibitor can diffuse into the clot and neutralize fibrin-bound
t-PA.
Injection of low doses of endotoxin (1 ,ug/kg body wt) in
rabbits, induces a very marked increase of PA-inhibitor activity
in blood without associated changes in platelet count, fibrinogen
level, and activated partial thromboplastin time (10). We have
now used this model to investigate the effect of high blood levels
of PA-inhibitor on the thrombolytic activity oft-PA in vitro and
in vivo.
Methods
Materials
Human t-PA (two-chain form), human plasminogen, and human fi-
brinogen were purified by published methods (15-17). Recombinant
human t-PA, obtained by expression of the t-PA gene in a mammalian
cell system, was supplied by Genentech Inc, South San Francisco, CA
(courtesy of Dr. C. F. Hoyng). Fibrinogen was digested with CNBr as
previously described (18). Fibrinogen was labeled with '25I using the
lodo-Gen procedure (19). Escherichia coli 011 1:B4 lipopolysaccharide
(LPS)W was purchased from Difco Laboratories, Inc., Detroit, MI. The
synthetic substrate D-Val-Leu-Lys-pNA (S-2251) was purchased from
KabiVitrum, Amsterdam, The Netherlands. D-Ile-Pro-Arg-CH2Cl, a
synthetic inhibitor of t-PA, is characterized elsewhere (20).
The t-PA preparations used in this study had a specific activity of
500,000 IU/mg as calibrated against the International Reference Prep-
aration for t-PA (83/517) (21). This specific activity is five times higher
than that reported in our previous studies in which t-PA was calibrated
against the International Reference Preparation of Urokinase (66/46).
In vivo experiments
New Zealand rabbits, weighing 1.9-2.5 kg, were anesthetized by intra-
muscular injection of 0.4 ml/kg body wt of Hypnorm (Duphar, Am-
sterdam, The Netherlands) containing 10 mg/ml fluanisone and 0.2
mg/ml fentanil. Additional Hypnorm (0.3 ml every 2 h) was administered
to maintain anesthesia. Venous blood samples (1 ml) were collected on
4% trisodium citrate (9 vol of blood plus 1 vol of anticoagulant), on
citrate plus D-Ile-Pro-Arg-CH2CI (2 x 10-4M final concentration) or on
heparin (10 U/ml). The blood samples were immediately chilled in melt-
ing ice. Plasma was isolated within 10 min of sampling by brief centrif-
ugation (2 min at 12,000 g) and kept on ice until tested, or was frozen
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immediately at -20°C. Injections of E. coli LPS (1 Ug/kg body wt) or
sterile saline (1 ml) were given intravenously to conscious rabbits 2 h
before the introduction of the jugular vein thrombus. Infusions of t-PA
were started about 3 h after endotoxin injection.
Lysis ofjugular vein clots with intravenous t-PA. The procedure for
the introduction of the radiolabeled ('25I-fibrinogen) thrombus in the
jugular vein of the rabbit, and for the quantitation of thrombolysis and
isotope recovery is described in detail elsewhere (22). All thrombolysis
experiments reported here were carried out in animals with fresh clots
aged for 30 min. t-PA was diluted to 24 ml with 0.15 M NaCl, 0.0 1%
Tween 80 and infused intravenously over 4 h by using a constant rate
infusion pump. The infusions were given systemically via the contralateral
marginal ear vein or locally through a catheter introduced via the ipsi-
lateral marginal ear vein and advanced into the immediate vicinity of
the clot. Thrombolysis, i.e., residual '25I-activity in the clots, was measured
within 10 min after the infusion had been terminated. Activator-induced
thrombolysis was calculated as the difference between the means of the
percentage thrombolysis in a given t-PA-infused group (A) and its control
group infused with solvent (C), divided by 100-C (22).
Thrombolysis induced by t-PA incorporated into the clot. Unanti-
coagulated blood (2 ml) from a donor rabbit was mixed with '25I-fibrin-
ogen and t-PA (25 IU/ml final concentration) and immediately injected
in an isolated jugular vein segment of recipient rabbits. The clot was
allowed to age for 30 min, the vein clamps were removed and the blood
flow restored, and thrombolysis was assessed after an additional 5 or
90 min.
Binding of infused t-PA to the jugular vein thrombus. This was mea-
sured in control and endotoxin-treated rabbits in the following way: A
dose of 40,000 IU of t-PA/kg body wt was infused over 1 h, the vein
segment was then opened and the clot recovered. The clot was washed
for 5 min in 0. 15 M NaCl and added to a plastic tube containing 2 ml
of citrated normal rabbit plasma. After isotope counting the samples
were incubated at 37°C. At intervals, 0.2-ml plasma samples were re-
moved for radioisotope counting and the extent of thrombolysis was
calculated from the amount of radioactivity released from the clot.
Infusion of t-PA into extracorporeal arteriovenous shunts. Rabbits
with an established jugular vein thrombus were heparinized (600 U/kg
i.v.); a portex red catheter (Portex Ltd., Hythe, Kent, England) was in-
troduced in the ipsilateral femoral artery and a portex blue catheter was
introduced via an ipsilateral marginal ear vein and advanced into the
immediate vicinity of the clot. The two catheters were connected via a
100-cm long silicon tubing (internal diam 4mm) filled with sterile saline
containing 50 U/ml heparin. Three-way valves were inserted on both
ends of the tubing. The volume of the arteriovenous shunt was 17 ml
and a constant flow rate of S ml/min was maintained by using a peristaltic
pump. Heparin (5 U/kg per min) was infused via the three-way valve at
the beginning of the arteriovenous shunt. t-PA (25,000 IU/kg body wt)
or solvent were infused over 4 h via this three-way valve and blood
samples were collected via the three-way valve at the end of the arterio-
venous shunt. Thus, t-PA was in contact with rabbit blood in the extra-
corporeal circulation for 3 min before reentering into the jugular vein.
Thrombolysis was assessed at the end of the infusion as described else-
where (22).
Lysis ofblood clots in the extracorporeal shunt by t-PA. Extracorporeal
arteriovenous shunts containing a radiolabeled whole blood clot were
produced in the following way. A portex red catheter introduced into a
femoral artery was connected to a closed reservoir (the filter compartment
of a blood transfusion set) containing the labeled clot. The reservoir was
then connected via a portex red catheter with the contralateral femoral
vein. The volume of the circuit was 15 ml and a constant flow rate of
12 ml/min was maintained with a peristaltic pump. The labeled blood
clot was produced as follows. Aliquots of 2 ml whole rabbit blood con-
taining '25I-fibrinogen (n200,000 cpm) were mixed with 4 IU ofthrombin
(Topostasin, Roche, Brussels, Belgium) and quickly aspirated in a silicon
tubing (4 mm i.d.). The blood was allowed to clot for 1 h at 37°C, then
segments of 1.5 cm length were cut off, yielding labeled blood clots of
-0.2 ml. The clots were poured into petri dishes and washed at room
temperature for 1 h in 0.15 M NaCl with several changes. This procedure
resulted in complete cross-linking of the fibrin in the clots (23). After
isotope counting, the clots were introduced into the reservoir of the ar-
teriovenous shunt. Heparin (5 U/kg per min) and t-PA (12,500 IU/kg
body wt) or solvent were infused over 2 h into the circuit before the
reservoir, and blood samples were collected via a three-way valve distal
to the reservoir. The contact time between t-PA and rabbit blood, before
the activator reached the clot was - 10 s. The extent of thrombolysis
was calculated at the end of the infusion by measuring the residual ra-
dioactivity in the clot.
In vitro studies
Inhibition offibrin-associated t-PA by PA-inhibitor. This was measured
in an in vitro system consisting of a radiolabeled blood clot immersed
in citrated rabbit plasma. The labeled blood clots were prepared as out-
lined above with the following modifications. t-PA (40 IU/ml final con-
centration) was added to the '25I-fibrinogen-blood mixture before addition
of thrombin. Clots were aged for 30 min at 37°C and then washed in
0.15 M NaCl for 15 min. After isotope counting, the clots were immersed
at 37°C in 2 ml control or PA-inhibitor-rich plasma. At intervals (up to
6 h) 0.2-ml plasma samples were removed and the extent of thrombolysis
was calculated from the amount of radioactivity released from the clot.
Lysis ofblood clots superfused with mixtures oft-PA and plasma or
whole blood. The effect of PA-inhibitor on t-PA-induced thrombolysis
of a radiolabeled blood clot was measured in the following way. A flat-
bottomed plastic tube (1.6 X 5 cm), containing 1 ml of plasma or blood
and a labeled clot, was placed in a waterbath at 37°C. Plasma and t-PA
were continuously transferred from a reservoir and a syringe, both kept
at room temperature, into the tube containing the clot. Plasma was per-
fused by means of a peristaltic pump at a constant rate of 1.2 ml/min
and t-PA by means of a constant rate infusion pump at a rate of 210
IU/min. Plasma and t-PA were mixed before delivery in the tube. The
clots were superfused with plasma containing 175 IU oft-PA/ml, which
had been mixed for either 5 or 70 s before contact with the clot. In the
experiments with whole blood, the infusion rate of t-PA was adjusted,
according to the hematocrit, in order to maintain a plasma concentration
of 175 IU/ml.
The volume in the tube was maintained constant by aspiration of
liquid via a tubing with the end fixed at the meniscus in the test tube.
Aliquots of plasma for assay oft-PA and PA-inhibitor were collected via
the aspirating tube, 25 and 50 min after the start of the infusion. The
extent of thrombolysis was calculated, 60 min after the start of the in-
fusion, from the residual radioactivity in the clot. In these experiments
radiolabeled clots with a volume of 25 jul (2.5 X 5 mm) were prepared
as outlined above. PA-inhibitor-rich blood and plasma were obtained
from endotoxin-treated rabbits 4 h after injection of 1 gg/kg body wt of
E. coli LPS. Plasma samples were always pools of at least three donor
animals, whereas whole blood of individual rabbits was used. Either
fresh plasma or plasma stored at -20°C was used. PA-inhibitor levels
were 16±6 U/ml in control and 265±65 U/ml in inhibitor-rich plasma
pools, measured as described below. Fibrinogen, plasminogen, and a2-
antiplasmin levels were similar in control and PA-inhibitor-rich plasma
and did not change significantly during the course of the experiments.
Effect oflung tissue slices on the lysis ofsuperfused blood clots. Slices
of lung tissue were prepared as follows. Rabbits were anesthetized by
intravenous injection ofsodium pentobarbital (25 mg/kg). After the chest
was opened, a portex yellow catheter was introduced into the pulmonary
artery and the lungs were perfused with 100 ml of0.15M NaCl containing
0.1% glucose. The lungs were then removed, separated from the heart
and other attached tissues, and transferred to petri dishes containing
serum-free Eagle's minimal essential medium (Gibco Ltd., Paisley, Scot-
land). Slices of 10 x 5 mm were cut out from the peripheral region of
the lungs with a razor blade. Several longitudinal and transveral incisions
were made on the lung slices in order to increase the external surface.
The slices were then rinsed in fresh medium and added to the tube
containing the radiolabeled clot. Lysis following superfusion with mixtures
of t-PA and plasma was then measured as described above.
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Other assays and procedures
t-PA activity in plasma was measured by the fibrin plate method (24) as
reported (15). The lower detection limit of this assay is 1 IU of t-PA/
ml. t-PA-related antigen was measured using a two-site immunoradio-
metric assay (25). PA-inhibitor activity was assayed by an amidolytic
method as described elsewhere (10), and expressed in units of t-PA in-
hibited by I ml of the assay solution. In this assay both plasma and
t-PA controls were acidified with 0.16 M HCI. Fibrinogen, a2-antiplasmin
and plasminogen were assayed as previously described (22, 26, 27). Ac-
tivated partial thromboplastin time and platelet count were performed
by standard laboratory assays. Gel filtration of plasma samples (0.5 ml)
was performed on an Ultrogel AcA 44 column (30 X 1.6 cm) equilibrated
with 0.02 M Tris HCI, 0.3 M NaCl buffer, pH 7.4, containing 0.01 M
trisodium citrate, and 0.02% Tween 80. The flow rate was 10 ml/h and
fractions of 1 ml were collected.
Results
All reported results were obtained with recombinant t-PA but
control experiments performed with t-PA isolated from mela-
noma cell culture gave very similar or identical results.
In vivo experiments
Lysis ofjugular vein clots with intravenous t-PA. The extent of
thrombolysis induced by t-PA in control and endotoxin-treated
rabbits is shown in Fig. 1. Systemic infusion oft-PA resulted in
a dose-dependent degree of lysis that was similar in both animal
groups. Locally infused activator caused a much higher degree
ofthrombolysis, which was also similar in control and endotoxin-
treated rabbits. Infusion of solvent resulted in a low degree of
spontaneous lysis. The isotope recovery (not shown) was >95%,
indicating that no significant losses of labeled material by em-
bolization had occurred.
The antigen levels of t-PA in the blood of rabbits during
infusion of the thrombolytic agent were proportional to the in-
fusion rate of t-PA (not shown). The t-PA levels (antigen and
activity) in rabbit plasma during systemic infusion of 150,000
IU oft-PA/kg body wt are shown in Fig. 2. In control animals
the t-PA activity recovered in the plasma euglobulin fraction
correlated well with the antigen levels (Fig. 2 A), whereas virtually
no activity (<1 IU/ml) was detected in the plasma of endotoxin-
treated animals (Fig. 2 B).
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Figure 1. Lysis ofjugular vein clots with intravenous t-PA. Thrombo-
lysis after systemic (A) or local (B) infusion of t-PA in control (open
bars) and endotoxin-treated (hatched bars) rabbits. Results are the
mean of three experiments. The vertical lines represent SD.
Gel filtration of plasma samples obtained from blood col-
lected on D-Ile-Pro-Arg-CH2Cl (Fig. 3) revealed that in plasma
ofcontrol animals most ofthe t-PA antigen eluted in the albumin
region, whereas in plasma ofendotoxin-treated animals it eluted
with an apparent molecular weight of 100,000. Because D-Ile-
Pro-Arg-CH2Cl completely prevents t-PA inhibition by PA-in-
hibitor in vitro (10), this finding indicates that inhibition of
t-PA in endotoxin-treated animals had occurred in vivo and not
in the test tube after blood sampling.
The plasma levels of fibrinogen, plasminogen, and a2-anti-
plasmin were not significantly different in the two groups of
animals and did not change during t-PA infusion (not shown).
Thrombolysis induced by t-PA incorporated into the clot. The
effect of PA-inhibitor on the lysis ofjugular vein thrombi made
from blood with added t-PA is illustrated in Fig. 4. The extent
of thrombolysis of t-PA-containing thrombi within 5 min after
removal of the vein clamps (i.e., during the 30-min interval of
clot aging) was much lower than after an additional 90 min, but
was similar in control and endotoxin-treated animals. The
plasma PA-inhibitor activity in endotoxin-treated rabbits was
225±70 U/ml.
Binding of infused t-PA to the jugular vein thrombus. t-PA
(40,000 IU per kg body wt) was infused over 1 h in rabbits with
jugular vein thrombus, and the clot was recovered at the end of
the infusion and incubated in normal rabbit plasma. No signif-
icant lysis (<10% in 20 h, n = 2) was observed with clots obtained
from either control or endotoxin-treated animals, indicating that,
if any t-PA is adsorbed onto the clot, its concentration remains
below the inhibiting capacity of control plasma.
Infusion of t-PA into extracorporeal arteriovenous shunts.
The following experiments were carried out to assess whether
the t-PA-PA-inhibitor complex has thrombolytic activity. t-PA
(25,000 IU/kg body wt) was infused over 4 h in the proximal
part of the femoro-jugular arteriovenous shunt. t-PA-induced
thrombolysis was 35% in control animals and undetectable in
endotoxin-treated rabbits (Fig. 5). The relatively high degree of
spontaneous thrombolysis observed in animals infused with sol-
vent is, most probably, due to the high flow rate of blood rein-
fused into the jugular vein. Assays of t-PA and gel filtration
analysis of blood samples collected from the distal part of the
arteriovenous shunt revealed complete inhibition oft-PA activity
and formation of t-PA-PA-inhibitor complex in endotoxin-
treated rabbits. In control animals peak t-PA activity in the ex-
tracorporeal loop ranged between 25 and 50 IU/ml of plasma.
This activity, however, declined to <10 IU/ml in the last hour
of infusion due to a spontaneous increase of the PA-inhibitor
level.
Lysis ofblood clots in the extracorporeal shunt by t-PA. A
radiolabeled clot was placed into an extracorporeal shunt con-
necting a femoral artery with the contralateral femoral vein.
t-PA (12,500 IU/kg body wt) was infused over 2 h into the prox-
imal part of the shunt and was mixed with blood about 10 s
before contact with the clot. The degree ofthrombolysis observed
at the end ofthe infusion is illustrated in Fig. 6. In control animals
the t-PA-induced lysis was on average 32% while in animals
with high circulating levels of inhibitor it was only 13%. This
degree of thrombolysis in endotoxin-treated rabbits is signifi-
cantly higher (P < 0.05) than the degree ofthrombolysis in con-
trol and endotoxin-treated rabbits infused with solvent. t-PA
activity in blood samples taken from the distal part of the ex-
tracorporeal circuit was 32±8 IU/ml in control animals and
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Figure 2. Plasma levels of t-PA antigen (.) and ac-
tivity (m) during infusion of t-PA. t-PA (150,000
IU/kg body wt) was infused over 4 h in control (A)
and endotoxin-treated (B) rabbits. Results are the
mean±SD of three experiments. Time 0 represents
the preinfusion value.
undetectable (<1 IU/ml) in endotoxin-treated rabbits. In this
latter group, the absence of free t-PA was also assessed by gel
filtration of samples collected on D-Ile-Pro-Arg-CH2Cl (not
shown).
In vitro experiments
Inhibition offibrin-associated t-PA by PA-inhibitor. Radiolabeled
blood clots containing t-PA (40 IU/ml) were immersed in control
or PA-inhibitor-rich rabbit plasma and the rate of lysis was cal-
culated from the released radioactivity. As shown in Fig. 7 A,
PA-inhibitor-rich plasma inhibits clot lysis markedly although
incompletely. For example, whole blood clots with incorporated
t-PA underwent 30% lysis in PA-inhibitor-rich plasma in 4 h as
compared with 62% in control plasma.
Addition of lung tissue slices (-200 mg) to this system did
not influence the rate of lysis ofclots immersed in control plasma
but significantly enhanced the rate of lysis of clots added to
PA-inhibitor-rich plasma. The rate of lysis of t-PA-free clots
immersed in control or PA-inhibitor-rich plasma was negligible,
both in the presence and in the absence of lung tissue
(Fig. 7 B).
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Lysis of superfused blood clots. Results of thrombolysis of
clots, superfused with rabbit plasma (1.2 ml/min) and t-PA (210
IU/min), which were mixed 5 s or 70 s prior to contact with the
clot are summarized in Fig. 8. In the absence oft-PA, the extent
of thrombolysis was negligible. When 175 IU/ml of t-PA was
added to control rabbit plasma, 22+4% lysis was obtained, com-
pared to 2±2% with PA-inhibitor-rich plasma. Similar results
were obtained when heparinized plasma or whole blood was
used instead of citrated plasma.
The addition of lung tissue slices, to the tube containing the
labeled clot, had no influence on t-PA-induced thrombolysis in
the presence of normal plasma, but markedly reduced the in-
hibitory effect of PA-inhibitor-rich plasma, resulting in 12±2%
lysis (Fig. 8 B). However, when t-PA was mixed for 70 s with
PA-inhibitor-rich plasma prior to contact with the clot, throm-
bolysis was again undetectable. The presence of lung tissue did
not result in a significant change (<10%) of the t-PA activity in
superfused control plasma nor of the PA-inhibitor activity in
PA-inhibitor-rich plasma. Mixtures ofPA-inhibitor-rich plasma
and t-PA thus yielded significant thrombolysis notwithstanding
the fact that only minimal t-PA activity (<2 IU/ml) could be
20
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j trogel AcA 44. Elution pattern of
l plasma samples from control (A) or en-
1 dotoxin-treated (B) rabbits during infu-
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' M final concentration). Similar results
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rabbits. - -, absorbance at 280 nm;
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Figure 4. Thrombolysis by t-PA incorporated into the clot. t-PA (0 or
25 IU/ml) was incorporated into the jugular vein thrombus in control
(open bars) and endotoxin-treated (hatched bars) rabbits. The extent
of thrombolysis was measured 5 min or 90 min after removal of the
vein clamps. Results are the mean±SD of three experiments.
measured in the superfused plasma. Such t-PA activity was not
significantly different from that measured in the superfused
plasma in the absence oflung tissue or in plasma that had reacted
70 s with t-PA.
Discussion
PA-inhibitor, a specific inhibitor oft-PA and UK recently iden-
tified in plasma, may play a role in the regulation and control
of physiologic fibrinolysis. Its low concentration in plasma has,
so far, hampered its purification, and present information con-
cerning its biological functions is mainly derived from plasma
Figure 5. Lysis ofjugular vein
thrombi after infusion of t-PA
into a femoro-jugular arteriove-
nous shunt. t-PA (25,000 IU/kg
body wt) was infused over 4 h
into the proximal part of the
shunt. The extent of thrombo-
lysis was measured at the end
of the infusion in control (open
bars) and endotoxin-treated
(hatched bars) rabbits. Results
are the mean±SD of three ex-
periments.
Figure 6. Lysis of blood clots
placed in an extracorporeal fe-
moro-femoral arteriovenous
shunt. t-PA (12,500 IU/kg
body wt) was infused over 2 h
into the proximal part of the
shunt in control (open bars)
and in endotoxin-treated(hatched bars) rabbits. Results
o 12,500 are the mean±SD of three to
LOF t -PA (lU/kg) four experiments.
samples with high levels ofPA-inhibitor activity. Very low doses
of endotoxin in rabbits induce a marked increase in the level of
PA-inhibitor (10), which allow studies on the effect of PA-in-
hibitor on thrombolysis induced by t-PA infusion.
Systemic or local infusion oft-PA produced comparable de-
grees of thrombolysis in control (PA-inhibitor-poor) and en-
dotoxin-treated (PA-inhibitor-rich) rabbits, even though the PA-
inhibitor was not saturated and no free t-PA activity could be
demonstrated in plasma from endotoxin-treated rabbits.
Our observation that human t-PA, injected into rabbits, cir-
culates mainly in its free form in the control animals and nearly
exclusively as t-PA-PA-inhibitor complex in endotoxin-treated
rabbits, raises the question whether t-PA-PA-inhibitor complex
has intrinsic thrombolytic capacity in vivo. The results of Fig.
5 show that the contact of t-PA with PA-inhibitor-rich blood
for -3 min results in complete inhibition of its thrombolytic
activity, suggesting that the (stabilized?) complex is inactive.
During systemic infusion, the elapsed time interval between en-
trance of t-PA into the rabbit's circulation and the contact of
the enzyme with the thrombus is 10 s. It is possible that
t-PA-PA-inhibitor complex may still be reversible when reaching
the fibrin clot, and that fibrin might dissociate the complex
yielding active t-PA. Attempts to measure t-PA accumulation
on the clot surface during t-PA infusion both in control and
endotoxin-treated animals were, however, unsuccessful.
t-PA incorporated into clots in vivo induces thrombolysis at
the same rate in control and endotoxin-treated animals. In vitro,
however, t-PA-containing blood clots immersed into PA-inhib-
itor-rich rabbit plasma lysed more slowly than clots immersed
in control plasma, indicating that protection, by fibrin, of t-PA
inhibition is less effective in vitro than in vivo.
To simulate the in vivo process of thrombolysis in vitro, a
radiolabeled blood clot was superfused with mixtures of t-PA
and PA-inhibitor-rich plasma. With an incubation time oft-PA
and PA-inhibitor of 5 s before contact with the clot, with a con-
centration of PA-inhibitor of 320 ng/ml (-7 nM) and of t-PA
of 340 ng/ml (=5 nM), and assuming a rate constant of the
interaction between the two proteins of 3. I07 M' s-', we an-
ticipate that 40% ofthe activator reaches the clot as free enzyme.
Notwithstanding this, no lysis occurred within 1 h, whereas 22%
lysis was obtained when t-PA was mixed with control plasma.
This indicates that even ift-PA accumulates on the clot surface,
PA-inhibitor efficiently neutralizes its activity in vivo. Replace-
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Figure 7. In vitro thrombolysis induced
by t-PA (40 IU/ml) incorporated into
blood clots immersed in control (-) or
PA-inhibitor-rich plasma (x). Experi-
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Each value is the mean±SD of four ex-
periments.
ment of citrated plasma by heparinized PA-inhibitor-rich plasma
or whole blood also did not result in clot lysis, suggesting that
calcium ions and blood cells do not interfere with the interaction
between t-PA and PA-inhibitor on the fibrin surface. However,
when a rabbit lung slice was added to the system in the vicinity
of the clot, significant lysis occurred following superfusion with
mixtures oft-PA and PA-inhibitor-rich plasma. Plasma samples
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Figure 8. In vitro lysis of whole blood clots superfused with mixtures
of t-PA or solvent and control rabbit plasma (A) or PA-inhibitor-rich
plasma (B). t-PA and plasma were mixed for 5 or 70 s (*) prior to
contact with the clot. Experiments were carried out in the absence
(open bars) and in the presence (hatched bars) of lung tissue slices. Re-
sults are the mean±SD of three to five experiments.
taken from the incubation mixture had only minimal t-PA ac-
tivity (<2 IU/ml). The lung tissue did not induce clot lysis in
the absence of t-PA nor enhanced the thrombolytic activity of
mixtures of t-PA and PA-inhibitor-poor plasma. It seems,
therefore, that in the presence of lung tissue the thrombolytic
activity of t-PA is, at least partially, protected from inhibition
by PA-inhibitor. Such protective effect by lung tissue was also
visible when t-PA-containing blood clots were incubated in PA-
inhibitor-rich plasma. This is not due to uptake or neutralization
of PA-inhibitor by the lung tissue because superfusion of the
lung tissue slice with PA-inhibitor-rich plasma without t-PA
was not associated with any change of the PA-inhibitor level.
Delayed inhibition of t-PA by PA-inhibitor in the presence
of lung tissue seems to occur at the fibrin surface and not in
solution, because no t-PA activity could be recovered in plasma
and because lung tissue does not influence the rate ofinteraction
between t-PA and PA-inhibitor in rabbit plasma in vitro. The
lung tissue did not restore the thrombolytic activity of mixtures
oft-PA and PA-inhibitor-rich plasma incubated for about 1 min,
indicating that it does not dissociate the (stabilized?) t-PA-PA-
inhibitor complex.
All these findings taken together suggest the existence ofone
or more tissue-derived components that play a role in the reg-
ulation of thrombolysis in vivo. Fig. 6 shows that a clot placed
in an extracorporeal loop in endotoxin-treated rabbits undergoes
significant lysis when t-PA is infused in the proximal segment,
suggesting that the interference with the inhibition of t-PA by
PA-inhibitor is caused by a secreted component. However, we
were unable to demonstrate any interference with t-PA-induced
thrombolysis in saline extracts of lung tissue or in conditioned
medium of short-term lung cultures. One major problem in
studying this thrombolysis modulating component is that it ap-
pears to be very labile and that there are no simple methods to
assay its activity.
In summary, our data show that the thrombolytic activity
of t-PA infused in rabbits with an experimental jugular vein
thrombosis is not affected by the presence of high concentra-
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tions of circulating PA-inhibitor, which rapidly inhibits t-PA.
Evidence is provided that one or more tissue-derived factors,
possibly ofendothelial cell origin, may modulate the interaction
between t-PA and PA-inhibitor at the level of fibrin, but the
nature, origin, and exact mechanism ofaction ofthis hypothetical
novel fibrinolytic component(s) remain(s) to be elucidated.
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